Scynexis Inc

NASDAQ:SCYX  
4.95
-0.32 (-6.07%)
Products

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Published: 12/06/2021 12:56 GMT
Scynexis Inc (SCYX) - Scynexis Announces Agreement With FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis.
Scynexis Inc - Initiating a Global Phase 3 Study to Evaluate Oral Ibrexafungerp As a Step-down Treatment for Invasive Candidiasis.